Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study

BACKGROUND/PURPOSE: Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor (ER) status. Before randomization in the phase III adjuvant ALTTO trial for HER2-positive disease, HER2 and ER were centrally reviewed by Mayo Clinic (Rochester, MN...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: McCullough, Ann E., Dell'Orto, Patrizia, Reinholz, Monica M., Gelber, Richard D., Dueck, Amylou C., Russo, Leila, Jenkins, Robert B., Andrighetto, Stefania, Chen, Beiyun, Jackisch, Christian, Untch, Michael, Perez, Edith A., Piccart-Gebhart, Martine J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4039190/
https://ncbi.nlm.nih.gov/pubmed/24395109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2827-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi